Kraton Corporation (NYSE:KRA), finished the day at $14.65, a rise of 9.66 per cent and a price that brought its market cap to $523.74 million. In the trailing twelve months, its return on investment (ROI) is 6% while the outstanding share count is 35.75 million shares but the size of available float is 30.89 million shares. The stock’s current price is lagging SMA-200 by -29.87% which is also 58% up from SMA-50. Reducing that period to a shorter term, we see the price is trailing 30.65% to the SMA-20.
HOUSTON, March 6, 2020 /PRNewswire/ — Kraton Corporation (NYSE: KRA) on March 6, 2020, said that it has completed the sale of its Cariflex™ business to Daelim Industrial Co, Ltd. (“Daelim”) for $530.0 million in cash saying that we are pleased to announce that we have completed the sale of our Cariflex business to Daelim Industrial Co, Ltd. We believe Daelim is well-positioned to invest in and grow the Cariflex franchise as it continues to expand its global business. We thank the Cariflex team for their significant contributions, not only for developing Cariflex, but for continuing to grow the business over the years, and we wish them continued success in the future.
Kevin M. Fogarty, Kraton’s President and Chief Executive Officer said that as previously communicated, we intend to use the net proceeds from the Cariflex sale principally for debt reduction. Following the closing of this important transaction, we remain committed to continuing to improve our overall capital structure, and this sale is an important step in that regard,” added Fogarty. J.P. Morgan Securities LLC acted as exclusive financial advisor to Kraton and Baker McKenzie served as legal advisor. UBS Securities LLC acted as exclusive financial advisor to Daelim and Paul Hastings LLP acted as legal advisor.
Volatility for the week was 9.74%, which was 2.10% in the previous month. The company closed the session with a trading volume of 487.61 thousand shares, below from its average daily trading volume of 586.51 thousand. It has been generating revenue of $1.78 billion.
When looking at performance, we see the stock demonstrating a weekly performance of 5.4% while keeping a monthly performance of 48.88%. Quarterly performance saw a drop of -11.16% and continued the negative trend with a yearly performance of -51.12% while showing YTD performance of -42.14% which was -40.4% for last six months. The 52-week range for the stock was 4.45 – 35.00 that put its current price at a premium of 229.21% to the 52-week low price whereas it is trading at a discount of -58.14% to the 52-week high price.
The Specialty Chemicals company’s EPS for trailing 12 months is $7.69 and it is estimated to be posting an EPS of $0.01 for the current quarter. The Beta number showed the stock is subject to risk 216% more than the market as a whole.